Value proposition

Rare inspiration. Changing lives.

Alexion, AstraZeneca Rare Disease was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca. For more than 30 years, Alexion’s mission has been to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, supportive technologies, and healthcare services. Dedicated to continuing its mission as part of AstraZeneca, Alexion recognizes that patients and caregivers are people first, and by understanding their experiences, Alexion is better able to serve their unique needs.

Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally.

GL/NP/0116
GL/NP/0095

Community Guidelines: https://bit.ly/39x9gqy

Biotechnology, Biopharmaceutical, Complement Inhibition, Metabolic Disorders, Neurology, Rare Diseases, Research and Development, hematology, and nephrology